New Hydrogel Design May Help Transplanted Islets Survive Better

Islet transplantation—moving healthy insulin-producing cells from a donor pancreas into someone with Type 1 diabetes—offers the potential for restored blood sugar control without lifelong insulin injections. However, the procedure faces a critical hurdle: the majority of transplanted islets die in the first weeks after transplantation.

The main culprit is oxygen deprivation. When islets are first transplanted, they lack access to the blood vessels needed to deliver oxygen. Over 70% of transplanted cells undergo cell death during this vulnerable early period, severely limiting transplant success and duration.

Researchers developed an injectable hydrogel—a biodegradable gel material—designed to protect transplanted islets and promote the formation of new blood vessels around them. The hydrogel is made from two natural polysaccharides: oxidized hyaluronic acid and carboxymethyl chitosan.

The hydrogel has a dual function: it carries oxygen-rich nanodroplets (tiny packages of a perfluorotributylamine compound) and releases vascular endothelial growth factor (VEGF), a protein that signals the body to build new blood vessels. Together, these components aim to solve both immediate oxygen starvation and longer-term blood vessel development.

When tested in the laboratory with low-oxygen conditions simulating transplant stress, islets embedded in the hydrogel survived much better than untreated islets. After 6 hours in zero oxygen, treated islets showed an 8.6-fold improvement in viability. After 48 hours, insulin secretion in response to glucose increased 4-fold compared to controls.

In mice with Type 1 diabetes induced by streptozotocin (a chemical that destroys insulin-producing cells), transplantation with the hydrogel-supported islets restored the animals' ability to produce their own insulin, reversed high blood sugar levels, and maintained graft function over time. The research team also observed enhanced formation of new blood vessels at the transplant site.

This research demonstrates that a carefully designed material can address two major obstacles to islet transplant success: immediate oxygen deprivation and inadequate blood vessel formation. The results in mice are encouraging and suggest the approach warrants further investigation.

However, this remains early-stage research. The hydrogel has been tested only in laboratory conditions and in mice. It has not been tested in humans, and many steps—including safety testing, refinement, and clinical trials—would be needed before this approach could help transplant patients. The findings represent one potential tool in efforts to improve islet transplant outcomes, not an imminent clinical solution.

Source: Regenerative biomaterials. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.